: Sequence of etanercept with the identified peptides after peptide mapping using the tryptic peptide, deglycosylated tryptic peptide (Deg), LysC and AspN digested peptides in Altebrel-6 is compared. The blank areas show the unidentified peptides by each of the methods. Aspartic acid 235 is the boundary of the TNFr and Fc domains. 
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Figure S6: MALDI-MS mass spectrum of permethylated N-glycans released from Enbrel-G. Mass spectrum A and B were the measurement of global permethylated N-glycans, in which each N-glycan was seen with sodium and potassium adduct as one pair; Mass spectrum C is the enlarged region representing the area from m/z 1810 to m/z 1910. The signals correspond to GlcNAc3Man4Gal1, GlcNAc4Man3Fuc1 and GlcNAc4Man3Gal1 N-glycans. 
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Figure S12: Dose-response curves of A) Control Enbrel-H1 and B) Control Altebrel-8 versus the in-house reference standard. Table S1 : List of observed modifications in etanercept. Modified amino acids are bolded and underlined in the sequence. Lack of lysine and leucine in C-terminal and N-terminal ends are shown by (-) 
